Search

Your search keyword '"Dinardo, Courtney D."' showing total 3,024 results

Search Constraints

Start Over You searched for: Author "Dinardo, Courtney D." Remove constraint Author: "Dinardo, Courtney D."
3,024 results on '"Dinardo, Courtney D."'

Search Results

1. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study: MYELODYSPLASTIC NEOPLASM

2. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

3. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

4. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

5. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community

6. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis

12. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine

13. Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

15. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

16. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

19. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

21. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

22. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

23. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

24. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

25. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

26. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

30. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

32. Hematopoiesis under telomere attrition at the single-cell resolution

33. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

34. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

36. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

37. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

40. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

41. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

42. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

43. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

44. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

45. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study

46. Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.

47. The impact of post‐remission granulocyte colony‐stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.

49. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience.

Catalog

Books, media, physical & digital resources